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Introduction
Classic experiments reported by Billingham, Brent and
Medawar more than 50 years ago [1] demonstrated that
skin grafts from major histocompatibility complex
(MHC) disparate donor mice would be accepted indeﬁ-
nitely when recipient mice had been exposed to donor
alloantigen in the neonatal period. These ﬁndings set
the stage for the use of experimental animal models to
be used in the quest to achieve transplantation toler-
ance. As these studies were reported, organ transplanta-
tion has evolved from an experimental therapy to the
mainstream treatment option for established organ fail-
ure. The previous hurdle of acute rejection has been
better controlled with the development of newer, more
potent, immunosuppressive medications and regimens
where combinations of immunosuppressive drugs are
used. The achievements of improved immunosuppres-
sion have, however, permitted the deleterious sequelae
of the long-term use of immunosuppressive agents as
well as chronic transplant dysfunction to become lead-
ing causes of recipient morbidity and in some cases
mortality as well as organ failure in long-term trans-
plant recipients [2,3]. Thus, although the technique of
transplantation has improved and pharmacotherapeutics
to limit acute rejection episodes have evolved, the harm-
ful ramiﬁcations of nonspeciﬁc immunosuppression still
persist, mandating the need for tolerance induction
therapies.
Experimental models have proven extremely useful for
the ﬁeld of transplantation to progress to its current state;
however, it is necessary to revisit these models to investi-
gate methods of tolerance induction in situations that are
more relevant to the clinical setting. This review discusses
various methods utilized in experimental models to
achieve alloantigen-speciﬁc immunologic unresponsive-
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Summary
Immunological tolerance or functional unresponsiveness to a transplant is
arguably the only approach that is likely to provide long-term graft survival
without the problems associated with life-long global immunosuppression.
Over the past 50 years, rodent models have become an invaluable tool for elu-
cidating the mechanisms of tolerance to alloantigens. Importantly, rodent mod-
els can be adapted to ensure that they reﬂect more accurately the immune
status of human transplant recipients. More recently, the development of
genetically modiﬁed mice has enabled speciﬁc insights into the cellular and
molecular mechanisms that play a key role in both the induction and mainte-
nance of tolerance to be obtained and more complex questions to be
addressed. This review highlights strategies designed to induce alloantigen spe-
ciﬁc immunological unresponsiveness leading to transplantation tolerance that
have been developed through the use of experimental models.
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els in the ﬁeld of transplantation.
Central transplantation tolerance
It is well known that the thymus is essential for both
T-cell maturation and the induction of tolerance to self
antigens. During maturation, thymocytes are positively
selected provided that their TCR has a ‘low’ intrinsic
afﬁnity for self MHC. The process of negative selection
results in the elimination of thymocytes that react to self-
MHC+ peptide with too high an avidity. The aim of these
two processes is to ensure that mature T cells emigrating
from the thymus will be able to recognize and respond to
peptides derived from the external environment bound to
self MHC molecules when they are presented in the
periphery but unable to respond to self peptides pre-
sented by MHC molecules of the host. Two of the ways
in which this natural process of deletion of self reactive T
cells has been exploited to try and induce tolerance to
donor alloantigens are described below.
Intrathymic administration of antigen
One approach to achieve central deletion of donor anti-
gen reactive T cells has involved intrathymic administra-
tion of alloantigen. Studies using this approach were
initiated in the 1960s and developed further by Posselt
et al. who conﬁrmed that the thymus was a suitable
transplant site. This study, in the rat model, demonstrated
the principle that intrathymic injection of allogeneic islets
together with lymphocyte depletion in the periphery
reversed diabetes and induced normoglycaemia [4]. Lim-
iting dilution analysis to determine the frequency of
donor alloantigen reactive cells remaining in the periph-
ery after intrathymic injection of the islets suggested that,
indeed, deletion of donor alloantigen reactive T cells had
occurred. This supposition was conﬁrmed by a study
using a TCR transgenic (Tg) model that demonstrated
directly that the deletion of donor reactive thymocytes
after intrathymic injection of donor leukocytes results in
the induction of operational tolerance [5]. Since this
observation, many other studies have conﬁrmed that
intrathymic injection of donor antigen or allopeptides
along with peripheral leukocyte depletion may lead to the
successful induction of operational donor-speciﬁc toler-
ance in rodent models [6–8]; however, the feasibility of
this approach in larger species is still questionable. Fur-
thermore, after the intrathymic delivery of allopeptide,
donor antigen persists in the thymus for only a deﬁned
period. Therefore, intrathymic delivery of donor antigen,
in contrast to establishment of a stable mixed chimaera
(see below), provides a transient presence of donor derived
antigen and stimulation of tolerant mechanisms, rather
than generating persistent deletion of thymocytes. There-
fore, additional strategies are needed to control alloreactive
T cells, after the intrathymic delivery of alloantigen, to
transplant a solid-organ graft in the long term [6].
In a clinical study, Remuzzi et al. investigated the safety
and tolerability of an intrathymic injection of donor
splenocytes peri-operatively [9]. Preliminary results
showed that although intrathymic injection did not have
any adverse consequences for the two patients who con-
sented to participate in this pilot study, this procedure
did not prevent acute cardiac allograft rejection. The
authors attributed this failure to prevent graft rejection to
the simultaneous use of immunosuppressive agents, sug-
gesting that speciﬁc conditions need to be optimized
before protocols involving intrathymic cellular adminis-
tration can be clinically exploited safely and effectively in
the future. More information about the potential impact
of the simultaneous administration of immunosuppressive
drugs on the efﬁcacy of intrathymic delivery of alloanti-
gen would be essential for future studies.
Mixed chimaerism
Early work by Sachs et al. revealed that irradiated mice
reconstituted with a mixture of T-cell depleted host and
donor bone marrow accepted donor skin grafts perma-
nently, rejected third party grafts and did not develop
graft versus host disease (GVHD) [10]. The success of
this experimental approach relied on the generation of
stable mixed chimaerism, a state in which donor and host
haematopoietic elements from multiple lineages coexist.
These and other studies showed that once host T cells are
sufﬁciently ablated to enable bone marrow engraftment to
be achieved, tolerance to fully MHC mismatched grafts
can be attained [11].
The requirement for pretransplant host conditioning
with sub-lethal irradiation and/or myeloablative agents
have limited the development and clinical application of
this approach to its fullest extent. Nevertheless, data from
rodent as well a large animal studies and more recently
clinical studies demonstrate that mixed chimaerism is an
effective approach for inducing tolerance to a deﬁned set
of donor alloantigens [12–17]. To progress this approach,
much work in rodent models has focused on replacing
these toxic therapies with less harmful protocols that
reduce host morbidity and have greater clinical potential.
Alternate approaches to myeloablative therapy were pur-
sued in mouse experimental models wherein the concom-
itant infusion of high-dose bone marrow with
nonmyeloablative regimens promoted the deletion of
donor reactive cells in the thymus [18–21]. Co stimula-
tory blockade has been reported to eliminate the need for
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multiple organ systems in experimental models [14,22–
24]. In large animal models, T-cell depletion has also
been shown to be effective in producing stable mixed chi-
maerism [25]. Early experimental evidence suggesting that
full chimaeras may reject donor grafts, a phenomenon
known as ‘split tolerance’, may also apply to the condi-
tion of stable mixed chimaerism unmatched for minor
antigens [26,27]. Although feasible in experimental mod-
els, matching of minor antigens may not be possible in
routine clinical practice. Therefore, it is necessary to over-
come the obstacle of ‘split tolerance’ before further strate-
gies utilizing nonmyeloablative conditioned mixed
chimaerism can be translated to the clinic [26].
An elegant study by Wekerle et al. revealed that lasting
chimaerism and donor speciﬁc transplantation tolerance
could be achieved through a protocol, which combined
the administration of a high dose of fully MHC
mismatched bone marrow with a single injection of anti-
CD40L and cytotoxic T-lymphocyte associated antigen
4-Ig (CTLA-4 Ig) [24]. An alternative to the use of poten-
tially toxic sub-lethal irradiation and myeloablative
agents, or cumbersome high doses of bone marrow, is the
administration of multiple doses under the cover of a sin-
gle agent such as anti-CD40L antibody [28]. Mice treated
with this protocol also developed robust haematopoietic
chimaerism and donor speciﬁc tolerance to fully MHC
mismatched skin grafts [28]. By extending these observa-
tions, Larsen et al. were able to develop a protocol using
busulfan, an alkylating agent that preferentially depletes
early haematopoietic stem cells, in conjunction with bone
marrow administration and simultaneous blockade of the
CD40 and CD28 co stimulatory pathways (using anti-
CD40L and CTLA-4 Ig respectively) to establish for titrat-
able levels of haematopoietic chimaerism that could result
in donor speciﬁc tolerance in a mouse skin allograft
model [14].
Recent clinical data suggest that long lasting mixed chi-
maerism may not be essential for the induction of toler-
ance to donor alloantigens. In recent patient studies, the
majority of recipients of HLA-haploidentical stem cell
transplantation with nonmyeloablative conditioning and
immunosuppressive GVHD prophylaxis were able to
achieve 100% donor cell engraftment and maintained
graft function without the onset of GVHD with a mis-
match of 2–3 HLA antigens [29,30].
Data from the experimental rat model have also dem-
onstrated the possibility that pretransplant conditioning
of the host may not always be required to attain the
long-term survival of donor derived cells. Injection of rat
embryonic stem like cells (RESCs) via the portal vein was
found to result in a state of mixed chimaerism in which
5–8% of donor cells resided in the white blood cell popu-
lation of recipient rats. Furthermore, rats with surviving
RESCs were able to accept cardiac allografts permanently
in a donor alloantigen speciﬁc manner [31]. One question
arising from this study is how the RESCs survive in an
allogeneic environment without host conditioning. Fas
ligand (FasL) expressed on RESCs may render peripheral
blood lymphocytes susceptible to apoptosis, a hypothesis
supported by in vitro studies using RESCs. Thus, it may
be possible to harness FasL dependent mechanism to
avoid rejection when donor cells are injected into a non-
myeloablated host [31].
In a recent work, multipotent bone-marrow derived
stromal cells, or mesenchymal stem cells (MSC) have
been shown to possess an immunoregulatory capacity, at
high doses, by suppressing the activation and proliferation
of both naı ¨ve and memory T cells in vitro [32–34]. Fur-
thermore, MSCs have shown promise in the facilitation
of haematopoietic stem cell engraftment and attenuation
of GVHD in limited clinical trials and have even been
reported to upregulate regulatory T-cell subsets (discussed
below) [35,36]. Although promising in vitro, MSCs have
been quite controversial in vivo. Recent data on the effects
of MSCs on immunomodulation in the rat allogeneic car-
diac transplant transplant model suggest that MSCs may
suppress T-cell proliferative responses in vitro; however,
translation in vivo was not achieved as allograft survival
was not prolonged and rejection responses were, in fact,
accelerated [37]. More work to substantiate these ﬁndings
in other experimental models is essential to progress for
this approach to large animal models.
Peripheral transplantation tolerance
Central deletion of auto or self reactive T cells in the thy-
mus is a relatively incomplete process. Therefore, the
immune system has developed additional strategies for
regulating the functional capacity of T cells with potential
autoreactivity that escape deletion in the thymus and
emerge into the periphery. Peripheral tolerance is the
term applied to these naturally arising mechanisms that
lead to anergy, deletion or suppression of self reactive T
cells in the periphery. Investigations in rodent models
have sought to develop these mechanisms to obtain
peripheral tolerance to alloantigens. Costimulation block-
ade is one approach that has been shown to induce
peripheral tolerance to alloantigens and is discussed in
the section below.
Blockade of co stimulatory molecules
Blockade of co stimulatory molecules at the time of allo-
antigen recognition has been shown in experimental
models to be a potential strategy for inducing peripheral
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on APCs) with CD28 (found on T cells) at the time of
antigen recognition induces T cells to produce IL-2, a
cytokine involved in their growth and proliferation [38].
Blockade of this pathway, in vitro, inhibits alloresponses
and induces T-cell anergy [39]. In rodent models, there
have been attempts to block signalling through the B7-
CD28 pathway using a CTLA-4 Ig fusion protein (a solu-
ble recombinant protein, which contains the extracellular
domain of human CTLA-4 fused to human immunoglob-
ulin Cc chain). CTLA-4 (CD152), a molecule that is
induced on activated T cells, is often referred to as a nat-
ural regulator of immune responsiveness. CTLA-4 binds
to CD80 and CD86 with higher avidity than CD28 and
can therefore compete with CD28 for binding to its
ligands.
CTLA-4Ig has been used to treat recipients at the time
of transplantation with promising results [40]. Interest-
ingly, the most effective approaches reported in rodent
models have combined CTLA-4Ig therapy with an infu-
sion of donor alloantigen. When CTLA-4Ig was adminis-
tered to mice treated with a donor speciﬁc transfusion
(DST) cardiac allografts were found to survive indeﬁnitely
[41]. The beneﬁcial effects of CTLA-4Ig have not been
found in every experimental model examined, however.
For example, the use of CTLA-4Ig monotherapy in pri-
mates has not been reported to be capable of inducing
long-term graft survival [42]. However, Zheng et al.
reported that treatment with CTLA-4Ig either pre or
post-transplantation resulted in skin allograft rejection in
mice pretreated with a tolerizing protocol of anti-CD40L/
DST, which led the authors to conclude that signalling
through CTLA-4 is required to achieve permanent graft
acceptance [43].
CTLA-4-Ig therapy has been explored in clinical trials
in solid organ and bone marrow transplantation. In the
latter setting, donor bone marrow, which was mismatched
with the recipient for one HLA haplotype, was cocultured
with irradiated recipient cells for 36 h in the presence of
CTLA-4Ig. Transfusion of these donor cells into the reci-
pient led to a reduction in the frequency of donor speciﬁc
alloreactive T cells and engraftment of the bone marrow.
In addition, only three of 11 transplant recipients showed
any evidence of GVHD thus suggesting that treatment of
donor bone marrow ex vivo with CTLA-4Ig could recon-
stitute haematopoiesis in vivo with a reduced risk of
GVHD [44]. Furthermore, recent evidence suggests that
CTLA4-Ig is critical in the induction of chimaerism
achieved in a model of mouse bone marrow transplanta-
tion and is independent of indolamine 2,3 dioxygenase
production [45].
Experiment models using CTLA-4Ig laid the ground-
work for further pharmacotherapeutic developments tar-
geted at the B7:CD28/CTLA4 pathway. The most
promising of these developments was the introduction of
Belatacept (LEA29Y), a derivative of CTLA-4Ig [46,47].
Belatacept differs from CTLA-4Ig by two amino acid
sequences, which confer a twofold greater ligation capac-
ity to CD80 and CD86. This increase in avidity allows for
an overall increase in the suppression of T-cell activation
in vitro when compared with CTLA-4Ig [46]. Originally
in nonhuman primate studies, Belatacept was found to
prolong renal allograft survival and inhibit donor-speciﬁc
alloantibody production both alone and in combination
with other traditionally used immunosuppressive regi-
mens [46]. These and other ﬁndings allowed for the
translation of Balatacept to renal transplant patients in
the clinics. To date, results of phase 2 trials (up to
12 months post-transplantation) comparing Belatacept to
cyclosporine in partially randomized studies across 22
centers in North America and Europe of over 200
patients suggest that Belatacept is not inferior to cyclo-
sporine in its ability to prevent acute rejection. In fact,
the results of this trial, so far, suggest that patients with
Belatacept-based therapy had improved renal function,
decreased calcineurin-related toxicity, and no thrombo-
embolic complications because of the exclusion of the
CD154 pathway [48]. Additionally, recent experiments in
nonhuman primates using neonatal porcine islet grafts
have shown long-term xenograft survival under the cover
of CD28–CD154 blockade with maintenance immunosup-
pression of sirolimus and belatacept [49]. Although
promising, further trials and vigilant follow-up is neces-
sary to assess accurately the efﬁcacy of these new thera-
peutic regimens incorporating belatacept.
A second co stimulatory pathway of importance is the
CD40 (found on APCs)/CD40L (CD154) (found on T
cells) pathway [40], which plays a pivotal role in the
development of CD4
+ T-cell responses [50]. Attempts to
induce tolerance by blockade of this pathway using
monoclonal antibodies either alone or in combination
with donor antigen have been successful in some
experimental donor-recipient combinations [43,51]. For
example, in a mouse skin allograft model, treatment with
anti-CD40L mAb and DST was found to lead to pro-
longed survival of skin grafts by inducing the deletion of
alloreactive CD8
+ T cells [51]. In addition, prolonged
survival of skin grafts could be abrogated by treating
recipients with anti-CTLA-4 mAb further conﬁrming that
signalling through CTLA-4 was required for prolonged
graft survival [43,51].
In general, CD4
+ T cells are more susceptible to co
stimulatory blockade than CD8
+ T cells; therefore, in
some rodent models the allograft survival can only occur
if the co stimulatory molecule blocking agent is used in
conjunction with an agent that depleted CD8
+ T cells
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LFA-1 pathways in the quest for transplantation tolerance,
it was demonstrated in a mouse model that concomitant
blockade of CD40L and LFA-1 through the use of mono-
clonal antibodies led to robust dominant tolerance to
pancreatic islet grafts, whereas targeting these co stimula-
tory pathways individually was only partially effective for
the induction of long-term graft survival [55].
Long-term acceptance of cardiac, renal and islet allo-
grafts in several murine and nonhuman primate models
was achieved with CD40 blockade using anti-CD154
monoclonal antibody as monotherapy or in conjunction
with CD28 blockade [40,56–60]. However, the so-called
tolerant states generated by anti-CD154 therapy alone
have been shown to disappear when therapy is with-
drawn, leading to rejection. Even with CD28 blockade,
anti-CD154 therapy must be sustained to promote per-
manent engraftment of cardiac or islet grafts [59,61,62].
Further, induced tolerant states in rodents tend to be
more robust when anti-CD154 therapy is combined with
donor antigens before transplantation tolerance is induced
[57–59]. Although promising results were reported in
experimental models, anti-CD154 therapy was found to
have the unexpected complication of thrombogenesis.
Some reports suggest that CD154 acts to stabilize thrombi
while others implicate CD154 in platelet activation [63].
Whatever the role that CD154 may play in transplanta-
tion tolerance, it is clear that this molecule acts via inde-
pendent pathways in a variety of cascades unrelated to
tolerance induction [64]. Additionally, recent work by
Larsen et al. has investigated the agonistic role that
human chimaeric antibodies to CD40 (Chi220) have in
abrogating immune responses. In these nonhuman pri-
mate models, the use of Chi220 alone was not impressive
in the prolongation of renal and islet allografts; however,
when combined with belatacept therapy allograft survival
was markedly improved. These data suggest that future
investigations of tolerance induction via costimulation
blockade are necessary [65,66].
Some of the newly discovered co stimulatory molecules
may also be targets for transplantation tolerance induc-
tion. In a mouse cardiac allograft model, mice deﬁcient
in the induced co stimulatory molecule – ICOS (ICOS
)/))
showed prolonged allograft survival. Additionally,
blockade of ICOS using an anti-ICOS antibody in con-
junction with cyclosporine administration led to sustained
allograft survival without the development of transplant
arteriosclerosis [67,68]. Manipulation of the co stimula-
tory pathway consisting of the constitutive activated T-cell
marker- herpes virus entry mediator (HVEM) and its
ligand LIGHT found on APCs has also shown promise
with regard to allograft survival. LIGHT
)/) mice treated
with cyclosporine showed prolonged survival of cardiac
allografts, decreased intragraft expression of IFN-c and
IFN-c induced chemokine inducible protein -10 [69]. As
the T cell–T-cell mediated LIGHT-HVEM co stimulatory
pathway is an important component of the immune
response, strategies to block or alter this pathway may
contribute to induction of tolerance. A recently deﬁned
CD28 homologue and co stimulatory molecule,
programmed death-1 (PD-1) and its ligands PDL-1 and
PDL-2 (homologue of B7) are also of therapeutic interest.
In a cardiac allograft model, CD28
)/) mice treated with a
PD-L1 Ig fusion protein showed prolonged allograft
survival, and in some cases permanent survival [70].
Treatment with PD-L1 Ig also prevented the development
of transplant vasculopathy and prevented islet allograft
destruction after anti-CD40L therapy, showing great
promise [67,71].
T-cell immunoregulation
Regulatory mechanisms in both the innate and adaptive
immune systems contribute to the overall outcome after
transplantation with T-cell mediated immunoregulation
playing a key role for inducing and maintaining periph-
eral tolerance in vivo. In both rodent and human systems,
there is an emerging consensus that donor reactive
immunoregulatory activity can be enriched within CD4
+
T cells.
The phenomenon of T-cell-mediated regulation in
transplantation tolerance is not new, but recently, a num-
ber of interesting ﬁndings have brought it back into the
limelight. Harnessing the capability of these suppressor
cells to regulate immune responses to not only self mole-
cules but also to foreign antigen is important as a poten-
tial therapy in transplantation. The ability of these
regulatory T cells to induce unresponsiveness to alloanti-
gen in vivo, in the absence of chronic immunosuppres-
sion, may inhibit the immune-mediated processes that
lead to long-term graft failure.
Infectious tolerance
Infectious tolerance is a process of peripheral immuno-
regulation, which is mediated by CD4
+ T cells and results
in the suppression of a primary or secondary immune
response by disabling effector CD4
+ T cells and convert-
ing them into regulatory T cells [72]. The concept of
infectious tolerance was originally described by Medawar
[1] and subsequently demonstrated by Qin et al. [73] in a
model where adult thymectomized mice were tolerized
with a cocktail of nondepleting anti-CD4 and anti-CD8
antibodies and accepted minor histocompatibility mis-
matched skin grafts. Infusion of naive syngeneic spleno-
cytes and grafting with fresh skin grafts 4 months later
Lessons from experimental models of tolerance Kingsley et al.
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and it was proposed that the T cells from tolerized mice
were able to guide the naive effector cells into a tolerant
state, rendering the tolerance achieved infectious (Fig. 1).
The phenomenon of infectious tolerance is not exclusive
to anti-CD4 therapy. Targeting other T-cell molecules as
well, such as CD154, at the time of antigen recognition
has also been shown to promote the development of
infectious tolerance [74].
CD25
+ CD4
+ regulatory T cells
As previously discussed, many autoreactive cells are
deleted centrally in the thymus; however, some manage to
escape. When these self reactive T cells emerge into the
periphery, they have the capacity to respond to self pep-
tides presented by self MHC molecules and therefore have
the capacity to trigger the onset of autoimmune diseases.
To prevent the development of these autoimmune dis-
eases, the immune system must maintain a state of toler-
ance and active regulation of self-reactive leukocytes [75].
Prevention of autoimmunity has been described by
‘active’ mechanisms of tolerance that utilize a unique sub-
set of T cells with regulatory function [76,77]. Suppressor
or regulatory T cells have been implicated as a key factor
in the active induction and maintenance of unresponsive-
ness to donor alloantigen in vivo, a characteristic that
may prove to be crucial in the development of strategies
to induce transplant tolerance [78].
Sakaguchi et al. were among the ﬁrst to demonstrate that
CD25 (IL-2R alpha) expression could be used as a tool to
enrich a sub population of CD4
+ T cells, which demon-
strated powerful regulatory activity [76]. CD25 is constitu-
tively found on approximately 10% of peripheral CD4
+ T
cells and <1% of peripheral CD8
+ T cells. Although many
studies within the last decade have demonstrated that
CD25
+ CD4
+ T cells can mediate tolerance to self antigens
[76,79–84], more recently, CD25
+ CD4
+ T cells have also
been found to regulate responses to alloantigens.
Work from our own laboratory has revealed that
CD25
+ CD4
+ T cells capable of regulating responses to
alloantigens in vivo (Fig. 2), can be isolated from mice
pretreated with a donor alloantigen, in the form of a spe-
ciﬁc transfusion (DST), under the cover of a nondepleting
anti-CD4 monoclonal antibody in both the induction and
maintenance phases of unresponsiveness [85,86]. In a
CBA (H-2k) Thymectomy
–14 Day
Anti-CD4 and anti-CD8 Ab
B10.BR
BALB/c skin grafts
B10.BR skin grafts
Skin grafts accepted
+4 months
CBA mice tolerized
infusion with 50 x 106 
naïve cells plus new 
B10.BR and BALB/c 
grafts 
(a)
Skin grafts
accepted 
Skin grafts
rejected 
(b)
50 x 106 tolerized cells 50 x 106 naive cells
T– cell deficient
B10.BR skin grafts accepted
BALB/c skin grafts rejected
0 2 4
Figure 1 Demonstration of infectious tolerance in a mouse model. (a) Thymectomized CBA mice were transplanted with B10.BR skin grafts and
given a tolerizing protocol of anti-CD4 and anti-CD8 antibodies. Four months later, infusion with 50 million naive splenocytes and transplantation
of a new B10.BR skin graft was unable to break donor speciﬁc tolerance. However, tolerance could be broken if T cells in tolerant mice were
depleted of CD4 T cells 7 weeks prior to transplantation of the second skin graft. (b) Fifty million spleen cells from tolerant and naive mice were
adoptively transferred into T-cell deﬁcient mice that were grafted with a B10.BR or BALB/c (third party skin). Cells from tolerant mice were able to
suppress skin graft in a donor speciﬁc manner as BALB/c skin grafts were rejected.
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demonstrated that CD25
+ CD4
+ regulatory T cells do not
mediate GVHD and are essential for tolerance induction
via co stimulatory blockade [87].
Such alloantigen speciﬁc CD25
+ CD4
+ regulatory T cells
are able to prevent skin graft rejection initiated by not only
CD4
+ [85,88] but also CD8
+ T cells [89], clearly indicating
that these cells have the potential to control T-cell medi-
ated rejection at multiple levels. Both our own studies [89]
and those of Lin et al. [90] have explored the mechanisms
by which CD25
+ CD4
+ regulatory T cells modulate CD8
+
T-cell mediated rejection using Tg CD8
+ T cells adoptively
transferred into tolerant mice. CD8
+ T-cell expansion was
found not to be impaired; however, effector functions of
CD8
+ T cells were prevented from developing.
Graca et al. established that both CD25
+ CD4
+ T cells
isolated from both naı ¨ve and tolerant mice could prevent
the rejection of skin grafts mismatched for minor alloan-
tigens [91]. CD25
+ CD4
+ T cells isolated from naive CBA
mice were found to prevent rejection of B10.BR skin
grafts when adoptively transferred into T-cell depleted
recipients along with naive unsorted cells. However, the
number of naive CD25
+ CD4
+ T cells required to regulate
skin allograft rejection was at least 10-fold higher than
CD25
+ CD4
+ T cells obtained from tolerant mice that
had previously been exposed to the donor minor alloanti-
gen. A similar observation was reported by Chen et al. in
a rat model [92]. Data from our laboratory have shown
that CD25
+ CD4
+ T cells isolated from naive mice adop-
tively transferred at equivalent cell doses as CD25
+ CD4
+
T cell from anti-CD4 (YTS177)/DST tolerized mice were
unable to prevent rejection of fully MHC mismatched
skin allografts [86]. Further information is required about
the frequency of T cells capable of regulating responses to
alloantigens that are present in naı ¨ve mice.
At present, a deﬁnitive marker to enrich regulatory cells
is under active investigation. Other populations of regula-
tory cells clearly exist, including CD8
+, CD8
+ CD28
),
TCR
+ CD4
) CD8
) (‘double negative’) and natural killer T
cells, thus CD25
+ CD4
+ cells may only represent one sub-
set. The context in which the regulatory activity arises may
impact the phenotypic and functional characteristics the
regulatory populations possess. For example, in our system,
CD25
) CD4
+ T cells isolated from anti-CD4 antibody/DST
Naïve CD45RBhigh
CD4+ T cells
CBA (H-2k)
Anti-CD4
Ab
Anti-CD4
Ab plus
DST
(B10 
blood)
–28 –27 0 
Harvest spleens
CBA Rag 1–/–(H-2k)
CD25+CD4+
Skin 
graft 
accepted
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Figure 2 Demonstration of immunoregulation by CD25
+ CD4
+ T cells and proposed mechanism of action. (a) CD25
+ CD4
+ T cells isolated from
CBA mice pretreated with anti-CD4 antibody plus DST are able to prevent B10 skin allograft rejection mediated by CD45RB
high CD4
+ effector T
cells. (b) Regulation mediated by CD25
+ CD4
+ T cells isolated from anti-CD4 antibody/DST treated mice is abrogated if recipient mice are adminis-
tered an anti-IL-10 or anti-CTLA-4 antibody at the time of cell transfer (and weekly thereafter). (c) Crosslinking of CTLA-4 on regulatory T cells
may lead to production of TGF-b which could bind to TGF-b receptors present on effector cells and prevent these cells expanding or homing to
the graft. Alternatively, TGF-b may enhance the ability of macrophages to produce IL-10 which could deliver a negative signal to effector cells
and prevent expansion or release of Th1 cytokines. Il-10 may also inhibit the function of APCs by down regulating B7 and MHC class II molecules.
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in our studies [85,86], whereas in other models,
CD25
) CD4
+ T cells from tolerant mice were able to pre-
vent skin graft rejection mediated by unsorted spleen cells.
This latter observation has been supported by data from
Chiffoleau et al. demonstrated that tolerance could be
transferred by thymic and splenic CD25
+ CD4
+ T cells, but
in 50% of the cases, this transferable tolerance was medi-
ated by splenic CD25
) CD4
+ T cells [93]. Taken together,
these ﬁndings suggest that CD25, although a useful marker,
may not be an effective way of identifying regulatory T cells
in all situations. Furthermore, reports describing distinct
subsets of T cells (Tr1) with IL-10 dependent suppressive
capacity are distinct to CD25
+ CD4
+ T reg in their low lev-
els of CD25 expression [94].
The mechanisms by which CD25
+ CD4
+ regulatory T
cells control responses to alloantigens are still under
investigation. Recently, cytokines have been found to play
an important role in mediating suppression in some sys-
tems in vivo. IL-10 and TGF-b play key roles in the sup-
pressive activity of alloantigen speciﬁc CD25
+ CD4
+
regulatory T cells [86]. As depicted in Fig. 2, Tregs iso-
lated from recipients pretreated with an anti-CD4/DST
tolerizing protocol and co-transferred with naı ¨ve effector
cells into T-cell deﬁcient mice failed to prevent skin graft
rejection when treated with an anti-IL-10 receptor anti-
body at the time of cell transfer and weekly thereafter,
whereas in the absence of anti-IL-10R antibody treatment,
all grafts were accepted [86] (Fig. 2). These ﬁndings also
support data obtained in a mouse colitis model [84].
Similarly, TGF-b1 mRNA was expressed at high levels in
accepted cardiac allografts from DST treated rats [95].
Moreover, neutralization of TGF-b in vivo from day 0 to
day 4 post-transplantation abrogated tolerance, as six of
six animals rejected their cardiac allografts.
In addition to cytokines, cell associated molecules have
been found to be involved in immunoregulation in some
situations. CD25
+ CD4
+ T cells have been shown in mice
to express constitutively surface and cytoplasmic CTLA-4
(CD152) [80]. Although CTLA-4 functions at the cell sur-
face, it is thought to be primarily stored intracellularly
where it continuously cycles to and from the cell surface
[96]. Data from our laboratory have shown that the popu-
lation of CD25
+ CD4
+ T cells, which suppress skin allo-
graft rejection are also dependent on signalling through
CTLA-4, as blockade of CTLA-4 with anti-CTLA-4 anti-
body led to acute rejection of skin allografts [86].
The interplay among IL-10, TGF-b and CTLA-4 in the
suppression of alloresponses is still not fully understood.
Recent data have demonstrated a link between IL-10 and
TGF-b, with IL-10 enhancing the expression of TGF-b
receptor on activated and resting cells [97]. As cross link-
ing of CTLA-4 has been shown to induce the production
of TGF-b in one system [98], it is possible that a common
mechanism of action may link CTLA-4 and IL-10 (Fig. 2).
An increasing list of molecules have found to be
expressed by T cells with regulatory activity, including cell
surface molecules such as CD62, CD103 and GITR (see
below) and the transcription factor Foxp3. CD25
+ CD4
+
regulatory T cells in the thymus and periphery have been
found to express the glucocorticoid induced tumor necro-
sis factor receptor (GITR) [99,100]. Signalling through
this receptor (following treatment with the monoclonal
antibody DTA-1) abrogated natural immune regulation
and induce autoimmunity in normal mice [100]. As the
authors hypothesize that GITR may play a role in immu-
noregulatory activity mediated by CD25
+ CD4
+ T cells,
we might suggest that this molecule or its ligand could be
of therapeutic interest in the generation of tolerance to
both self and alloantigens. Investigations into the role of
signalling through GITR in the induction and mainte-
nance phases of tolerance have shown that their pathways
may play a differential role, abrogating the induction of
unresponsiveness but not affecting immunoregulation
once it is established [101].
Overall, the models presented may have to be revisited,
in the light of recent theories regarding the impact that
memory T cells (Tm) may have on the induction of toler-
ance. The concept of ‘heterologous immunity’ proposed
by Larsen’s group refers to chronic immunologic activa-
tion by various environmental stimuli leading to a popu-
lation of Tm which can cross react with alloantigens.
These Tm seem to be resistant to conventional induction
therapies and may prove to be a hurdle for newer thera-
peutic approaches [102,103]. Although newer protocols
involving central and peripheral tolerance may control
naı ¨ve populations of effector cells, T cells that acquire
immunologic memory are unique in phenotype and func-
tion when compared with their naı ¨ve counterparts. Spe-
ciﬁcally, Tm have a decreased threshold of activation and
proliferation and also exhibit the ability to proliferate
homeostatically, rendering this population difﬁcult to
contain with current experimental tolerance protocols
[103]. Moreover, the beneﬁts of tolerance induction may
be broken after transplantation in the face of chronic
infection, as suggested by certain experimental models
[104,105]. Thus, through the use of more complex rodent
models, it may be possible to develop experimental sce-
narios that more accurately reﬂect the distinct environ-
ments encountered when attempting to manipulate the
immune response to a transplant in humans.
Concluding remarks
It has become increasingly clear that research in experi-
mental models has allowed for greater insight into the
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have also established the principles in which new therapeu-
tic approaches can be devised to enable robust tolerance to
alloantigens to be achieved for the future of clinical trans-
plantation (Table 1). Great care must be taken when trying
to translate data from laboratory models to clinical appli-
cation. Developing rodent models such that they replicate
more accurately the distinct elements of the immune
microenvironment that is present in humans is important
to ensure that the ﬁndings in rodent models are more
robust. Nevertheless, data derived from animal models can
be extremely useful in directing the next phases of research
required to develop novel therapeutic strategies for clinical
application. Moreover, questions that arise as a result of a
clinical investigation can often be explored very effectively
by returning to rodent models to design new experiments
that will provide clues as to how to approach the clinical
problem. For example, the effects of current immunosup-
pressive regimens on tolerance inducing strategies could be
explored initially through carefully designed experiments
in rodent models of transplantation tolerance. Controlled
clinical trials developed based on proof of concept and
mechanistic studies in experimental models can yield
promising results [106–111].
Furthermore, it is imperative to remember that mani-
pulation of one aspect of the immune response may have
a deleterious effect on other important immune pathways.
Although the generation and expansion of CD25
+ CD4
+
T cells may be a strategy to induce donor speciﬁc trans-
plantation tolerance, it has been well documented in a
mouse tumour model that CD25
+ regulatory T cells sup-
press tumour speciﬁc responses, leading to tumour
growth. It is only when this subset is eliminated that
tumour immunity can be restored [112–114]. Conversely,
elimination of the CD25 subset to re-establish responses
to tumour antigens has also been shown to lead to auto-
immune destruction of melanocytes [115].
So what is the future direction of research into trans-
plantation tolerance using experimental models? The
identiﬁcation of new co stimulatory pathways and the
current interest in chemokines and their receptors may
offer new targets for immune intervention that need to be
fully explored in experimental models before such strate-
gies can be considered and selected appropriately for fur-
ther development. Although there is much information
regarding the role regulatory T cells play in suppressing
responses to self antigens, more research is needed to
examine the role these cells play in regulating responses
Table 1. Summary of strategies to induce transplantation tolerance in rodent models.
Type of
tolerance Rodent model Strategy Suggested mechanism of action
Reference
Central Mouse islet allograft model Intrathymic injection of
alloantigen
Deletion of alloreactive T cells [4,8]
Mouse cardiac allograft model Intrathymic injection of
alloantigen
Deletion of alloreactive T cells [5]
Rat islet and cardiac allograft
models
Intrathymic injection of
Class I peptide
Suppression of donor reactive CTLs [7]
Mouse skin allograft model Bone marrow infusion
and co stimulatory
blockade
Mixed chimerism [24,28]
Mouse skin allograft model Bone marrow infusion,
co stimulatory blockade
plus busulfan
Mixed chimerism [14]
Rat cardiac allograft model Stem cell infusion via
portal vein
Mixed chimerism [35]
Peripheral Mouse skin allograft model Tolerizing
protocol- thymectomy,
anti-CD4 and anti-CD8 Ab
Infectious tolerance-alloreactive
T cells disabled
[43–45]
Mouse skin allograft model Generation and adoptive
transfer of CD25
+ CD4
+
regulatory T cells
Suppression of alloreactive
T cells- involvement of IL-10
and CTLA-4
[59,72,84,94]
Mouse cardiac allograft model Co stimulatory blockade Prevents optimal T-cell activation/
proliferation- alloreactive T cells
anergized and can undergo
apoptosis
[83,93,101,103–105]
Mouse skin allograft model Co stimulatory blockade As above [95,99]
Mouse islet allograft model Co stimulatory blockade As above [64,102]
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to determine deﬁnitive markers of transplantation toler-
ance. Studies in animal systems may enable this goal to
be achieved.
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